ArticleMovement disorders : official journal of the Movement Disorder Society2026
Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global research synergy: Advancing fundamental Parkinson's research through international collaboration.Journal of Parkinson's disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundRecent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease-associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response.
objectivesThe Accelerating Medicines Partnership® Parkinson's Disease (AMP PD) program is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations, managed by the Foundation for National Institutes of Health (FNIH). The program aims to advance the molecular and clinical characterization of PD through deep, longitudinal profiling of patient data and biosamples, with the goal of identifying and validating diagnostic, prognostic, and progression biomarkers for PD.
methodsLongitudinal proteomic profiling, both targeted and untargeted, was performed on cerebrospinal fluid (CSF) and plasma samples. The resulting datasets are publicly accessible via the AMP® PD Knowledge Platform.
resultsThe proteomic datasets enable differential protein analyses and can be used to explore molecular alterations associated with PD progression and heterogeneity.
conclusionsThese studies contribute to the broader AMP PD initiative by providing the research community with a harmonized proteomics dataset. As part of the larger AMP PD data, this work provides the PD community with a harmonized and accessible proteomics dataset that can be utilized for discovery, hypothesis generation, and validation of users' own research. © 2026 Technome. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.